YASAR YILDIZ1, YUKSEL KUCUKZEYBEK1, AHMET ALACACIOGLU1, HALIL TASKAYNATAN1, IBRAHIM YILDIZ2, UMUT VAROL1, LEYLA DEMIR3, MURAT AKYOL1, TARIK SALMAN1, UTKU OFLAZOGLU1, TOYGAR KALKAN1, MUSTAFA OKTAY TARHAN4
1Clinics of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey - 2Clinics of Medical Oncology, Acıbadem University Atakent Hospital, Istanbul, Turkey - 3Clinics of Biochemistry, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey - 4Institute of Oncology, University of Dokuz Eylül, Izmir-Turkey
Background: The role of molecular markers in ovarian cancer is still a matter of debate. This study was conducted to determi- ne the clinical significance of serum Omentin-1 in epithelial ovarian cancer (EOC) patients in the current matched case-control study.
Material and methods: Fourty-one patients with advanced EOC and 41 healthy people were included in the study. Serum Omentin values were measured by quantitative ELISA method.
Results: The median serum Omentin-1 values was 46.6 pg/ml in patients and this was significantly higher than healthy con- trols (median 35.5) (p=0.045). There was positive correlation between serum omentin and serum CA-125 levels (r = 0.34, p =0.028). We found no relationship between serum Omentin-1 levels and any prognostic parameters analyzed, including age of the patients, histology, tumor grade, stage of the disease, debulking surgery and response to chemotherapy. Survival analysis did not show statisti- cally significant effect of serum Omentin-1 level on overall survival (p = 0.91)
Conclusions: These results indicated that serum Omentin-1 values were significantly elevated in patients with advanced ove- rian carcinoma compared to healthy people. Further studies with a greater number of patients are required to confirm the importan- ce of serum Omentin-1 levels in ovarian cancer.
Serum Omentin-1, advanced stage, Overall survival, Ovarian Cancer.